Intech Investment Management LLC Takes $58,000 Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Intech Investment Management LLC bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 10,092 shares of the biotechnology company’s stock, valued at approximately $58,000.

Several other large investors also recently bought and sold shares of the stock. AlphaQuest LLC grew its holdings in shares of Enanta Pharmaceuticals by 16.4% during the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 3,137 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Enanta Pharmaceuticals during the 4th quarter worth about $26,000. FMR LLC grew its stake in Enanta Pharmaceuticals by 18.9% during the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock valued at $511,000 after purchasing an additional 7,839 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Enanta Pharmaceuticals in the third quarter valued at about $122,000. Finally, Geode Capital Management LLC raised its stake in shares of Enanta Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after purchasing an additional 14,575 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Analysts Set New Price Targets

ENTA has been the topic of a number of recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ:ENTA opened at $5.71 on Friday. The company has a market capitalization of $121.81 million, a PE ratio of -1.15 and a beta of 0.48. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.71 and a 12-month high of $17.80. The business has a 50 day moving average of $6.41 and a two-hundred day moving average of $8.24.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. Equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly bought 45,000 shares of Enanta Pharmaceuticals stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average cost of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 13.89% of the company’s stock.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.